Nervous System Channel
Topics
Medications
Quicklinks
Related Channels

Info on Orally Disintegrating Carbidopa-Levodopa

The U.S. Food and Drug Administration has approved orally disintegrating carbidopa-levodopa (Parcopa®) for Parkinson's disease as well as Parkinson-like symptoms due to:
 
  • Manganese poisoning
  • Encephalitis
  • Carbon monoxide poisoning.
 
These tablets are especially designed to dissolve rapidly on the tongue, without the need for water. This is particularly beneficial for people who have trouble swallowing tablets, which is often the case with Parkinson's disease.
 
Prior to beginning treatment with this drug, review the drug's safety info with your healthcare provider. Orally disintegrating carbidopa-levodopa is not right for everyone. For example, those with malignant melanoma, a history of stomach or intestinal ulcers, or any lung problems may need to consider an alternative form of treatment.
 
(Click Orally Disintegrating Carbidopa-Levodopa for more information on this drug, including how it works, possible side effects, what to do in cases of overdose, and more.)
 
 

Info on Orally Disintegrating Carbidopa-Levodopa

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.